...
首页> 外文期刊>The journal of clinical investigation >Glucose deprivation–induced aberrant FUT1-mediated fucosylation drives cancer stemness in hepatocellular carcinoma
【24h】

Glucose deprivation–induced aberrant FUT1-mediated fucosylation drives cancer stemness in hepatocellular carcinoma

机译:葡萄糖剥夺诱导的异常Futer1介导的岩藻糖基化驱动肝细胞癌的癌症茎

获取原文
           

摘要

Rapidly growing tumors often experience hypoxia and nutrient (e.g., glucose) deficiency because of poor vascularization. Tumor cells respond to the cytotoxic effects of such stresses by inducing molecular adaptations that promote clonal selection of a more malignant tumor-initiating cell phenotype, especially in the innermost tumor regions. Here, we report a regulatory mechanism involving fucosylation by which glucose restriction promotes cancer stemness to drive drug resistance and tumor recurrence. Using hepatocellular carcinoma (HCC) as a model, we showed that restricted glucose availability enhanced the PERK/eIF2α/ATF4 signaling axis to drive fucosyltransferase 1 ( FUT1 ) transcription via direct binding of ATF4 to the FUT1 promoter. FUT1 overexpression is a poor prognostic indicator for HCC. FUT1 inhibition could mitigate tumor initiation, self-renewal, and drug resistance. Mechanistically, we demonstrated that CD147, ICAM-1, EGFR, and EPHA2 are glycoprotein targets of FUT1, in which such fucosylation would consequently converge on deregulated AKT/mTOR/4EBP1 signaling to drive cancer stemness. Treatment with an α-(1,2)-fucosylation inhibitor sensitized HCC tumors to sorafenib, a first-line molecularly targeted drug used for advanced HCC patients, and reduced the tumor-initiating subset. FUT1 overexpression and/or CD147, ICAM-1, EGFR, and EPHA2 fucosylation may be good prognostic markers and therapeutic targets for cancer patients.
机译:由于血管形成不良,迅速增长的肿瘤往往经历缺氧和营养(例如,葡萄糖)缺乏。肿瘤细胞通过诱导促进更恶性肿瘤引发细胞表型的克隆选择的分子适应来响应这种应力的细胞毒性作用,尤其是在最内肿瘤区域。在此,我们报告了涉及岩藻糖基化的调节机制,葡萄糖限制促进癌症茎,以驱动耐药性和肿瘤复发。使用肝细胞癌(HCC)作为模型,我们展示了限制葡萄糖可用性通过ATF4直接结合到Fut1启动子的直接结合来驱动岩藻糖基转移酶1(Fut1)转录来增强Perk /EIF2α/ ATF4信号轴。 Fut1过表达是HCC的糟糕预后指标。 Fut1抑制可以减轻肿瘤起始,自我更新和耐药性。机械地,我们证明了CD147,ICAM-1,EGFR和Epha2是Fut1的糖蛋白靶标,其中这种岩藻糖基化将在解毒的AKT / mTOR / 4EBP1信号传导以驱动癌症茎。用α-(1,2) - 碳化抑制剂对索拉非尼(Sorafenib)敏化HCC肿瘤的处理,用于高级HCC患者的一线分子靶向药物,并降低肿瘤引发子集。 Fut1过表达和/或CD147,ICAM-1,EGFR和Epha2岩氧化可能是癌症患者的良好预后标志物和治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号